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Cancer-Specific Mortality, Cure Fraction, and Noncancer
Causes of Death Among Diffuse Large B-Cell Lymphoma
Patients in the Immunochemotherapy Era
Nadia Howlader, PhD, MS1,2; Angela B. Mariotto, PhD1; Caroline Besson, MD, PhD3; Gita Suneja, MD4; Kim Robien, PhD2;
Naji Younes, PhD2; and Eric A. Engels, MD, MPH5
BACKGROUND: Survival after the diagnosis of diffuse large B-cell lymphoma (DLBCL) has been increasing since 2002 because of
improved therapies; however, long-term outcomes for these patients in the modern treatment era are still unknown. METHODS: Using
Surveillance, Epidemiology, and End Results data, this study first assessed factors associated with DLBCL-specific mortality during
2002-2012. An epidemiologic risk profile, based on clinical and demographic characteristics, was used to stratify DLBCL cases into
low-, medium-, and high-risk groups. The proportions of DLBCL cases that might be considered cured in these 3 risk groups was esti-
mated. Risks of death due to various noncancer causes among DLBCL cases versus the general population were also calculated with
standardized mortality ratios (SMRs). RESULTS: Overall, 8274 deaths were recorded among 18,047 DLBCL cases; 76% of the total
deaths were attributed to DLBCL, and 24% were attributed to noncancer causes. The 10-year survival rates for the low-, medium-,
and high-risk groups were 80%, 60%, and 36%, respectively. The estimated cure proportions for the low-, medium-, and high-risk
groups were 73%, 49%, and 27%, respectively; however, these cure estimates were uncertain because of the need to extrapolate the
survival curves beyond the follow-up time. Mortality risks calculated with SMRs were elevated for conditions including vascular dis-
eases (SMR, 1.3), infections (SMR, 3.1), gastrointestinal diseases (SMR, 2.5), and blood diseases (SMR, 4.6). These mortality risks were
especially high within the initial 5 years after the diagnosis and declined after 5 years. CONCLUSIONS: Some DLBCL patients may be
cured of their cancer, but they continue to experience excess mortality from lymphoma and other noncancer causes. Cancer
2017;000:000-000. VC 2017 American Cancer Society.
KEYWORDS: cancer-specific survival, causes of death, cure, diffuse large B-cell lymphoma, noncancer causes of death, rituximab
with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP), standardized mortality ratio, Surveillance, Epidemiology,
and End Results (SEER).
INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) in the United
States and represents approximately a fourth of NHL cases.1 Since 2002, standard therapy has involved immunochemo-
therapy (ie, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]).2-5 In particular,
with the advent of rituximab in 2002, survival has improved dramatically for DLBCL patients, especially among those
with advanced-stage disease.2,6-9 Although the majority of DLBCL patients treated with R-CHOP respond to treatment,
approximately 20% to 40% of patients either will fail to achieve remission or will relapse.3,10,11 Many DLBCL patients
can be long-term survivors of their disease in the R-CHOP era.12
Nonetheless, it is often difficult to determine whether an individual patient is cured when he or she becomes free of
symptoms and other signs of lymphoma. On the other hand, at the population level, cure occurs when DLBCL patients as a
whole do not experience any excess mortality due to lymphoma after some time has passed since the diagnosis. This can be
evaluated with 2 approaches: 1) determining when risk of death reaches the same level as mortality in the general population
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(ie, with a relative survival approach) and 2) identifying
when there is no risk of death from DLBCL itself, which
can be determined from the underlying causes of death
(CODs) reported on the death certificate (ie, with a cause-
specific survival approach).13 Under either approach, cure is
defined as the point when the survival curve reaches a pla-
teau; in other words, the excess risk of death from DLBCL
appears to be zero.
DLBCL patients are at risk of dying of conditions
other than their malignancy, which may arise from treat-
ment side effects or comorbidities associated with
DLBCL. Some notable medical issues that lymphoma
patients face include immunosuppression, venous throm-
boembolism, and complications of treatment such as
cardiovascular disease, diabetes mellitus, and gastric
ulcers.14-17 Information about long-term survival among
DLBCL patients with respect to these conditions, based
on population-based data in the R-CHOP era, is lacking.
To address these issues, we used population-based
data from the US Surveillance, Epidemiology, and End
Results (SEER) program. We first assessed factors associ-
ated with DLBCL cancer-specific mortality in the
R-CHOP era (ie, DLBCL cases diagnosed from 2002
onward). We created an epidemiologic risk profile for
DLBCL cases that incorporated important demographic
and clinical characteristics at the time of diagnosis. Using
the risk profile, we stratified DLBCL cases into low-,
medium-, and high-risk groups. We then estimated the
proportion of DLBCL cases who could be considered
cured of their malignancy. Finally, we assessed the risk of
death from main noncancer causes among the DLBCL
cases in comparison with the general population.
MATERIALS AND METHODS
Data Source
All adult (age  20 years) DLBCL cases diagnosed during
2002-2011 in the SEER-13 registries were identified with
the SEER lymphoma subtype recode variable.18 These 13
registries cover approximately 14% of the US population.
Patients with a first or only cancer diagnosis of DLBCL
were included (4398 patients who had a prior cancer before
they were diagnosed with DLBCL were excluded from the
analysis). Cases with primary mediastinal large B-cell lym-
phoma (histology code 9679; n 5 177) were excluded
because these cases typically do not receive R-CHOP. We
also excluded human immunodeficiency virus (HIV)–
infected DLBCL cases (determined with the SEER HIV
flag) because the treatment and outcomes differ for such
patients; because Iowa opted out of submitting the HIV
flag, we excluded this registry from the analysis. Finally, we
excluded cases with missing values for the Ann Arbor stage
(n 5 899) or the poverty index (n 5 3), which were used
in the risk score calculations (discussed later).
COD
Underlying CODs were ascertained by cancer registries
from death certificate codes obtained from the National
Center for Health Statistics. The International Classifica-
tion of Diseases, Tenth Revision, was used to code CODs.
CODs can be misattributed on death certificates. To cor-
rect for known errors with COD attribution, the SEER
program recently developed a special COD variable that
indicates whether the death was due to the primary cancer
diagnosis or other causes.19,20 We used this variable to
assign a broad set of CODs to capture deaths due to
DLBCL among people with an incident DLBCL diagno-
sis. Specifically, for DLBCL cases in SEER, we considered
a death as due to DLBCL if it was coded to a death from
any hematologic malignancy, another cancer (if the per-
son had DLBCL as the only incident cancer, a COD
coded to another cancer site was assumed to be a miscod-
ing), or a related neoplastic condition.20 Separately, addi-
tional noncancer CODs were assessed on the basis of
clinical judgment as complications of DLBCL or its treat-
ment, and they were adapted from the Know Your Chan-
ces risk chart produced by the SEER program.21,22
Supporting Table 1 (see online supporting information)
lists the International Classification of Diseases, Tenth Revi-
sion, codes used to define the DLBCL and noncancer
COD outcomes.
Statistical Analysis
DLBCL cases were followed from diagnosis until death,
the development of another malignancy, loss to follow-
up, or December 31, 2012 (maximum follow-up of 11
years). Prior studies have examined the risk of second can-
cers in NHL patients,23-25 and second cancers can compli-
cate the determination of whether CODs are due to the
primary cancer. As a result, we chose to censor cases when
they developed a second malignancy; few DLBCL cases
(n 5 215 [1.2%]) exited the study because of second
malignancies. Among these 215 cases, leukemia (n 5 42
[20%]), lymphoma (n5 41 [19%]), and digestive system
cancers (n5 37 [17%]) were the 3 most common second
cancers.
We used multivariate Cox proportional hazards
models to identify independent predictors of DLBCL-
specific death. The available predictors included the age at
diagnosis, sex, race, Hispanic ethnicity, marital status,
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county-level poverty,26,27 Ann Arbor stage,28 and initial
course of therapy (chemotherapy or radiation). Interac-
tions between stage and radiation were considered in the
model but were dropped because they were not signifi-
cant. Each DLBCL case received a risk score calculated as
the sum of the coefficients estimated from the Cox model
multiplied by their covariate values. Although chemother-
apy and radiation were included as adjustment factors in
the multivariate model, we did not include them in the
calculation of risk scores because treatments were not ran-
domly assigned and it would be inappropriate to make
clinical judgments about treatment on the basis of the
associations. In addition, chemotherapy data from SEER
registries are incomplete.29 Thus, the remaining terms in
the risk model can be interpreted as the estimated risk of
DLBCL-specific mortality after adjustments for any
effects of treatment. Patients were classified into tertiles by
categorization of the individual risk scores into low-,
medium-, and high-risk groups.
For each risk group, DLBCL-specific survival curves
were calculated with an actuarial method. We then used a
mixture cure model to estimate the cure proportion30-32
separately for each risk group. The model assumed that
the overall DLBCL population was a mixture of 2 groups:
a cured group that experienced no excess mortality and an
uncured group that continued to experience excess mor-
tality throughout follow-up. The cure proportion was
modeled with a logit link. We assumed that the DLBCL-
specific survival times of the uncured group followed a
log-logistic distribution; for sensitivity analyses, we fitted
2 additional models with Weibull and log-normal distri-
butions. We used the SASmacro PSPMCM for fitting the
TABLE 1. Characteristics of Diffuse Large B-Cell Lymphoma Patients and Predictors of Cancer-Specific
Death in the R-CHOP Era (SEER-12 Registries, 2002-2011).
Patient Characteristic (n 5 18,047) No. %
Cox Model
Hazard Ratio 95% CI P
Age at diagnosis <.0001
20-59 y 6551 36.3 1.0
60-69 y 3889 21.6 1.5 1.4-1.6
70-79 y 4176 23.1 2.3 2.2-2.5
80 y 3431 19.0 3.6 3.4-3.9
Sex <.0001
Male 9615 53.3 1.0
Female 8432 46.7 0.9 0.8-0.9
Race .0009
White 14,434 80.0 1.0
Black 1292 7.2 1.2 1.0-1.3
Other 2321 12.9 1.1 1.0-1.2
Ethnicity <.0001
Non-Hispanic 15,562 86.2 1.0
Hispanic 2485 13.8 1.2 1.1-1.3
Ann Arbor stage <.0001
I 5243 29.1 1.0
II 3811 21.1 1.2 1.1-1.3
III 2853 15.8 1.6 1.5-1.8
IV 6140 34.0 2.4 2.2-2.6
Chemotherapy <.0001
Yes 14,051 77.9 0.5 0.4-0.5
No/unknown 3996 22.1 1.0
Radiation <.0001
Yes 4149 23.0 0.8 0.7-0.8
No/unknown 13,898 77.0 1.0
Marital statusa <.0001
Yes 10,072 55.8 0.8 0.8-0.9
No 7975 44.2 1.0
County-level poverty .0621
Low 8741 48.4 1.0
Medium 8971 49.7 1.1 1.0-1.2
High 335 1.9 1.1 0.8-1.4
Abbreviations: CI, confidence interval; R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; SEER, Surveillance, Epidemiology,
and End Results.
The SEER-12 registries include the Atlanta, Connecticut, Detroit, Hawaii, New Mexico, San Francisco–Oakland, Seattle–Puget Sound, Utah, Los Angeles, San
Jose–Monterey, rural Georgia, and Alaska Native tumor registries. Patients diagnosed between 2002 and 2011 were followed until December 31, 2012.
a For marital status, the no category consists of single, divorced, separated, widowed, and unknown groups.
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mixture cure model.32 We compared the observed
DLBCL-specific survival curves with the predicted curves
to assess the model fit. Prior research suggests that the sur-
vival of people alive 2 years after a DLBCL diagnosis
approaches the survival of the general population (ie, their
DLBCL-specific mortality tends to be zero).12 Therefore,
for a sensitivity analysis checking the reliability of our cure
model estimates, we assessed conditional survival 2 years
after the diagnosis for DLBCL cases (overall and for
patients known to have been treated with chemotherapy).
The idea behind plotting these conditional survival curves
was to determine whether there was any flattening overall
or in the treated group that would suggest a time after
which there was no excess mortality from lymphoma (ie,
evidence of a cure).
For noncancer CODs, we compared the observed
number of deaths with the expected number of deaths in
the general population with standardized mortality ratios
(SMRs). We divided the follow-up into 0 to 59 and 60
months after the DLBCL diagnosis to distinguish between
early and late events. Ninety-five percent confidence inter-
vals (CIs) for the SMRs and tests for differences in the
SMRs across follow-up periods were calculated under the
assumption of a Poisson distribution. SEER*Stat and SAS
were used to perform the SMR analysis.33
RESULTS
Our analysis included 18,047 DLBCL cases diagnosed in
SEER areas (Table 1). The majority of the cases were male
(53.3%), were white (80.0%), were of non-Hispanic ethnic-
ity (86.2%), were married (55.8%), and lived in counties
associated with low or medium poverty levels (48.4% or
49.7%). The median age at diagnosis was 66 years. More
than a third of the cases (34.0%) were diagnosed with stage
IV disease. Most (77.9%) were treated with chemotherapy,
whereas radiotherapy was reported for only 23.0% of cases.
Overall, there were a total of 8274 deaths. Of these
deaths, 6288 (76%) were due to DLBCL, and 1986
(24%) were attributed to noncancer causes. In the multi-
variate Cox model, DLBCL-specific mortality was associ-
ated with an older age at diagnosis (hazard ratio [HR] for
an age of 60-69 vs 20-59 years, 1.5 [95% CI, 1.4-1.6];
HR for an age of 70-79 vs 20-59 years, 2.3 [95% CI, 2.2-
2.5]; HR for an age of 80 vs 20-59 years, 3.6 [95% CI,
3.4-3.9]), black race (HR for blacks vs whites, 1.2 [95%
CI, 1.0-1.3]), Hispanic ethnicity (HR, 1.2 [95% CI, 1.1-
1.3]), and an advanced stage at diagnosis (HR for stage IV
vs stage I, 2.4 [95%CI, 2.2-2.6]), whereas lower DLBCL-
specific mortality was observed in females (HR, 0.9 [95%
CI, 0.8-0.9]) and married patients (HR, 0.8 [95% CI,
0.8-0.9]). The receipt of chemotherapy or radiation was
also associated with a lower risk of DLBCL-specific death.
In Figure 1, observed and predicted DLBCL-specific
survival curves from the cure model (dotted and solid lines,
respectively) are shown for low-, medium-, and high-risk
DLBCL cases. For the low-risk group, the observed sur-
vival curve showed some flattening at the end of the study
follow-up period. In contrast, the survival curves for the
Figure 1. DLBCL-specific survival among DLBCL patients observed and estimated with a cure model. Observed DLBCL-specific
survival curves are shown with dashed lines for low-, medium-, and high-risk groups, and the corresponding predicted DLBCL-
specific survival curves from a cure model are shown with solid lines. For the cure model, we assumed that the DLBCL-specific
survival times of the uncured group followed a log-logistic distribution. The estimated cure proportions are shown by the hori-
zontal lines for the 3 groups. DLBCL indicates diffuse large B-cell lymphoma.
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medium- and high-risk groups appeared to be still falling,
and this indicated that DLBCL cases in these groups con-
tinued to die of their lymphoma. The 10-year DLBCL-
specific survival rates for the low-, medium-, and high-risk
groups were 80%, 60%, and 36%, respectively.
The predicted DLBCL-specific survival from the cure
model seems to fit the observed survival curves well (Fig.
1). The predicted cure proportion was 73% (95% CI,
72%-76%) for low-risk patients, 49% (95% CI, 47%-
52%) for medium-risk patients, and 27% (95% CI, 25%-
30%) for high-risk patients. Importantly, the estimated
cure fractions (shown by the horizontal lines in Fig. 1) were
far below the end of the survival curves, and this indicated
that the extrapolation required to reach the cured propor-
tion was substantial. The median survival times for the
uncured patients were 23.1, 18.1, and 6.6 months in the
low-, medium-, and high-risk groups, respectively. In sensi-
tivity analyses, we refitted cure models under the assump-
tion of Weibull and log-normal distributions (Supporting
Figs. 1 and 2, respectively [see online supporting informa-
tion]). With these Weibull and log-normal distributions,
the predicted cure proportions were 78% and 63% for
low-risk patients, 59% and 41% for medium-risk patients,
and 37% and 26% for high-risk patients, respectively.
In Figure 2, we present estimates of DLBCL-specific
survival conditional on being alive 2 years after the diag-
nosis. Among all DLBCL cases who survived 2 years after
their diagnosis and even among those cases with known
chemotherapy use, the curves appear to be still decreasing
at the end of the follow-up period.
As shown in Table 2, DLBCL cases had an elevated
risk of death due to noncancer causes overall in compari-
son with the general population (SMR, 1.41 [95% CI,
1.35-1.48]). Mortality risks were highest for a number of
specific conditions such as infection (SMR, 3.13 [95%
CI, 2.76-3.54]), including pneumonia/influenza (SMR,
1.68 [95% CI, 1.31-2.12]) and septicemia (SMR, 1.88
[95% CI, 1.36-2.53]); gastrointestinal diseases (SMR,
2.50 [95% CI, 2.08-2.97]), including ulcer disease
(SMR, 4.92 [95% CI, 2.45-8.88]) and chronic liver dis-
ease and cirrhosis (SMR, 2.95 [95% CI, 2.11-4.0]); and
blood diseases (SMR, 4.64 [95%CI, 3.06-6.75]). Mortal-
ity was also elevated for vascular diseases (SMR 1.35,
[95% CI, 1.25-1.44]), including coronary heart disease
(SMR 1.47, [95%CI, 1.35-1.60]). Patients had a reduced
risk of mortality due to neurological diseases (SMR, 0.65
[95% CI, 0.50-0.82]) and specifically Alzheimer disease
(SMR, 0.53 [95% CI, 0.37-0.74]). Mortality was not dif-
ferent than what was expected for stroke, diabetes mellitus,
chronic obstructive pulmonary disease, urinary tract dis-
eases, and accidents and injuries. SMRs for some conditions
(eg, infections, gastrointestinal diseases, and blood diseases)
were dramatically elevated within the initial 5 years after
the diagnosis but declined after 5 years (P< .05; Table 2).
DISCUSSION
This is the first population-based study assessing cure out-
comes and deaths due to noncancer causes for DLBCL
patients in the R-CHOP era. Previous research has shown
that survival after DLBCL has improved considerably
Figure 2. DLBCL-specific survival overall and among patients with known chemotherapy use for patients surviving 2 years after
their diagnosis. DLBCL-specific survival curves are shown for (A) all patients and (B) those treated with chemotherapy. The black,
solid line in each panel represents unconditional survival, whereas the black, dashed line represents survival after the DLBCL
diagnosis conditional on a patient being alive at 2 years, as indicated by the vertical line. DLBCL indicates diffuse large B-cell
lymphoma.
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over time. The 5-year DLBCL-specific survival rate went
from 37% in 1975 to 66% in 2005.34 Despite this dra-
matic improvement, we have found that more than three-
quarters of all deaths among DLBCL patients in the R-
CHOP era are still due to DLBCL. Although noncancer
deaths constitute a smaller fraction, our study noted ele-
vated risks from a number of noncancer CODs in com-
parison with the US general population.
We applied a cure model to SEER data for newly
diagnosed DLBCL cases. Cure models allow survival infor-
mation on patients with sufficiently long follow-up to be
split into 2 components: the proportion cured (those who
do not experience any mortality from their disease, even
many years after their diagnosis) and the proportion des-
tined to die of their disease. For DLBCL, the estimated
cure proportions were 73% for low-risk patients, 49% for
medium-risk patients, and 27% for high-risk patients
according to a log-logistic distribution. From the sensitivity
analyses, in which we refitted additional mixture cure mod-
els with Weibull and log-normal distributions, the cure
proportions were 63% to 78% for low-risk patients, 41%
to 59% for medium-risk patients, and 26% to 37% for
high-risk patients. Because of the range of cure estimates, it
is difficult to be certain about the proportion of DLBCL
patients who are cured. Cure proportions are challenging
to estimate because they typically rely on extrapolations
beyond the observed survival time. As stressed by
others,30,31,35 fitting a cure model requires a long follow-
up period after the diagnosis. We had only 11 years of
follow-up, which may not be long enough to provide accu-
rate estimates of cure proportions. The DLBCL-specific
survival curves that we present show leveling off, but
importantly, there is still some decrease at the end of the
follow-up period. The continued gradual decline in
DLBCL-specific survival over time was also seen when we
estimated survival among patients alive 2 years after their
diagnosis. These results indicate that although there is
likely a fraction of patients who are cured, it is difficult to
be definitive on this point, and at least some long-term sur-
vivors of DLBCL may continue to die of their malignancy.
Even though outcomes are often favorable for
DLBCL patients, especially among those treated with
immunochemotherapy, some patients experience late
relapse. For example, Maurer et al12 reported that 8% of
patients relapse within 2 to 7 years after the diagnosis.
The relapse rate is lower with increasing time after the
diagnosis but is still approximately 4% at 5 years.11 This
pattern of late relapse is seen in patients with early-stage
disease,11,36 a favorable International Prognostic Index,11
or extranodal disease involvement.11 The late-relapse
TABLE 2. SMRs for Specific Noncancer CODs Among Diffuse Large B-Cell Lymphoma Cases Diagnosed in
the Modern R-CHOP Era
Noncancer COD





Deaths SMR 95% CI
Observed
Deaths SMR 95% CI
Observed
Deaths SMR 95% CI
Total 1788 1.41 1.35-1.48 1479 1.56 1.48-1.64 309 0.99 0.88-1.10 <.0001
Vascular diseases 784 1.35 1.25-1.44 639 1.44 1.33-1.56 145 1.04 0.88-1.23 .005
Coronary heart disease 533 1.47 1.35-1.60 439 1.58 1.43-1.73 94 1.11 0.9-1.36 .002
Stroke 100 1.00 0.81-1.21 82 1.07 0.85-1.33 18 0.76 0.45-1.20 .162
Infection 261 3.13 2.76-3.54 226 3.57 3.12-4.07 35 1.74 1.22-2.43 <.0001
Pneumonia/influenza 71 1.68 1.31-2.12 56 1.73 1.31-2.25 15 1.49 0.84-2.46 .596
Septicemia 43 1.88 1.36-2.53 36 2.07 1.45-2.87 7 1.26 0.51-2.60 .149
Diabetes mellitus 51 1.08 0.80-1.42 43 1.18 0.86-1.59 8 0.73 0.31-1.44 .197
Lung diseases 185 1.29 1.11-1.48 159 1.47 1.25-1.71 26 0.73 0.48-1.07 .008
COPD 83 0.84 0.67-1.04 64 0.86 0.66-1.10 19 0.79 0.47-1.23 .735
Gastrointestinal diseases 128 2.50 2.08-2.97 108 2.76 2.26-3.33 20 1.64 1.00-2.54 .037
Ulcer disease 11 4.92 2.45-8.80 9 5.2 2.38-9.87 2 3.96 0.48-14.3 .299
Chronic liver disease and cirrhosis 41 2.95 2.11-4.00 37 3.45 2.43-4.76 4 1.25 0.34-3.2 .078
Blood diseases 27 4.64 3.06-6.75 26 5.95 3.89-8.72 1 0.69 0.02-3.84 .662
Venous thromboembolism 2 1.27 0.15-4.59 2 1.65 0.2-5.95 0
Urinary tract diseases 54 1.19 0.89-1.55 42 1.22 0.88-1.65 12 1.08 0.56-1.88 .704
Neurological diseases 65 0.65 0.5-0.82 50 0.68 0.5-0.9 15 0.56 0.31-0.92 .506
Alzheimer disease 34 0.53 0.37-0.74 24 0.52 0.33-0.77 10 0.57 0.27-1.04 .822
Accidents and injuries 69 1.13 0.88-1.43 54 1.16 0.87-1.52 15 1.01 0.57-1.67 .582
All other noncancer CODs combined 179 1.20 1.03-1.39 146 1.37 1.16-1.61 33 0.77 0.53-1.08 .002
Abbreviations: CI, confidence interval; COD, cause of death; COPD, chronic obstructive pulmonary disease; R-CHOP, rituximab with cyclophosphamide, doxo-
rubicin, vincristine, and prednisone; SMR, standardized mortality ratio.
Bolded SMRs are significantly different from 1.00 (P < .05). A blank indicates that because of 0 observed deaths, the SMR, 95% CI, and P value were not
calculated.
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phenomenon in this patient population is manifested in
our DLBCL-specific survival curves (Fig. 1) and explains
why we could not confidently estimate the cure fractions.
DLBCL patients also have an elevated risk of dying
of a number of other conditions, as shown in Table 2.
Mortality risks were elevated for vascular disease (SMR,
1.35) and specifically for coronary heart disease (SMR,
1.47), this risk being significantly elevated during the first
5 years after the DLBCL diagnosis. Mortality from infec-
tions (SMR, 3.13), including pneumonia/influenza (SMR,
1.68) and septicemia (SMR, 1.88), was also elevated.
Given that DLBCL patients are immunocompromised by
their disease and subsequent treatment with chemotherapy,
we were not surprised to see an elevated risk of death from
infection, and the SMRs for infection declined over time.
Mortality from blood diseases (eg, anemia, thrombocytope-
nia, and clotting disorders) was elevated (SMR, 4.64), espe-
cially during the first 5 years after the diagnosis (SMR,
5.95), and may likewise be related to complications of
DLBCL or its treatment. Previous research has shown that
common CODs in this patient population include
therapy-related deaths, such as complications from hemo-
lytic anemia, infections, side effects of chemotherapy drugs,
and other causes.4,11,12 Doxorubicin-related cardiotoxicity
is a major noncancer COD among DLBCL patients
treated with R-CHOP.12 Venous thromboembolism can
also occur as a treatment complication,12,17 although mor-
tality from this condition was not elevated in our study.
The reduced mortality due to neurological diseases (SMR,
0.65) and specifically Alzheimer disease (SMR, 0.53) may
partly indicate a bias; that is, patients with severe dementia
or another debility may not be evaluated or treated for
DLBCL. This hypothesis is supported by the finding of a
reduced incidence of DLBCL diagnoses among elderly
patients with neurologic diseases.37
The accuracy of our analyses depends on the methods
used by the National Center for Health Statistics to assign
underlying CODs. Assigning an underlying COD for an
individual with multiple medical problems, including can-
cer, is challenging because there is often uncertainty about
the chain of events leading to death. For our cure models,
we used an algorithm recently developed by SEER to cap-
ture cancer-specific deaths.20 According to this algorithm,
any cancer COD is attributed to DLBCL-specific death if
DLBCL was the patient’s only diagnosed cancer. The
assumption here is that if the person had DLBCL as the
only incident cancer, then CODs indicating another cancer
were miscoded; for example, the COD may incorrectly
indicate the site of metastasis. This approach was reason-
able in our study because of this issue of miscoding on
death certificates and also because we censored people if
they actually developed a second cancer. With respect to
our SMR analysis, it is possible that undercounting or
overcounting of deaths occurred. Diabetes and hyperten-
sion deaths, for example, are probably undercounted
because they are often reported as contributing factors
rather than the underlying COD.38 We considered these
CODs separately from DLBCL-specific deaths, even
though some of the conditions are caused by DLBCL or its
treatment. It is thus possible that some of these noncancer
deaths would have contributed as events had we estimated
cure proportions with relative survival, which compares all-
cause mortality in a diseased cohort with that in the general
population.39 However, the number of noncancer CODs
was small in comparison with the number of DLBCL-
specific deaths, and the cancer-specific curves and relative
survival curves were similar (not shown).
There are several strengths of our study. Our results
are population-based and incorporate high-quality US
cancer registry data. SEER registries reliably capture
DLBCL cases in their catchment areas, and they have
complete follow-up information for more than 95% of
cases, so reporting of survival is reliable.1 Our results are
more generalizable than those from single centers, and
clinical trials are unlikely to include representative sam-
ples of older, sicker, and low-income patients.40,41 There-
fore, our study best reflects outcomes among unselected
DLBCL patients experiencing typical patterns of care.
A few limitations should be noted. Because we relied
on data collected by cancer registries, the risk model that
we used to categorize DLBCL cases lacked some useful
clinical variables (eg, performance status and serum lactate
dehydrogenase level) included in clinical risk models.8,42,43
With these other models, it may be possible to identify
very low-risk groups that indeed show clear evidence of a
cure.12 Another limitation of our approach is that we could
not examine death from second cancers because the algo-
rithm that we used assigned CODs only for first cancers.
However, second cancers after a primary NHL have been
assessed in other studies, and although they are an impor-
tant issue, they are rare events.23 Lastly, we lacked robust
data on treatment and especially chemotherapy use.29
A final limitation of our analysis is that we could not
determine which patients received R-CHOP, although we
were able to incorporate SEER data on the receipt of any
chemotherapy. Thus, the estimates that we present in our
article may be less useful for treating clinicians than for
researchers and policymakers interested in the entire pop-
ulation of recently diagnosed DLBCL patients. Survival
for patients who received chemotherapy was better than
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survival for the cohort overall (Fig. 2). However, even in
the treated group, the survival curves were still falling at
the end of follow-up. As for the cohort overall, this obser-
vation makes it difficult to determine with certainty the
proportion of cured patients in the chemotherapy-treated
group.
In conclusion, using population-based data, we
show that DLBCL patients diagnosed in the modern R-
CHOP treatment era still experience substantial mortality
due to their cancer and other noncancer causes. Although
DLBCL-specific mortality levels off over time, there is no
clear plateau, and even patients who achieve 2-year sur-
vival are still at risk of dying of their lymphoma. Mortality
from vascular diseases, infections, and blood diseases is
also particularly elevated. Additional clinical research is
needed to develop optimal treatments for DLBCL and
strategies to prevent long-term relapse and treatment-
related deaths. In the interim, clinicians should be aware
of these long-term risks, and the impact of recently pub-
lished strategies for improving the care of DLBCL survi-
vors should be evaluated.44
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